Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neurological disorder arising from primary rubella infection of the brain, characterized by chronic encephalitis. It is believed to be due to a persistence or reactivation of rubella virus infection. It usually manifesting between 8–19 years of age.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for progressive rubella panencephalitis.
3 publications have been identified in PubMed for progressive rubella panencephalitis. Research spans Review / Meta-Analysis (67%) and Case Report / Case Series (33%).
Stensbøl AB (2025). [PMID: 41489140](https://pubmed.ncbi.nlm.nih.gov/41489140/). *Ugeskr Laeger*. [Case Report / Case Series]
Mubbashir Z (2025). [PMID: 39924947](https://pubmed.ncbi.nlm.nih.gov/39924947/). *Brain Behav*. [Review / Meta-Analysis]
Makhupane T (2024). [PMID: 39425042](https://pubmed.ncbi.nlm.nih.gov/39425042/). *BMC Public Health*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 4:55 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning progressive rubella panencephalitis
Updated Mar 5, 2026
A report from Florida highlights cases of congenital rubella syndrome, emphasizing the need for increased awareness and vaccination efforts. The findings aim to inform public health strategies to prevent further cases.